Ionis Pharmaceuticals reported an EPS of -$1.41 (or adjusted EPS around -$1.15), missing consensus EPS estimates (around -$1.23), but significantly exceeding revenue expectations with $203 million in total revenue.The company has shown a pattern of revenue beats in recent quarters despite a year-over-year decline in Q4 total revenue.
Ionis maintains a strong current ratio of approximately 2.79, indicating good short-term financial health despite ongoing unprofitability. Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. Operating within the Zacks Medical – Drugs industry, Ionis has been making strides with its innovative drug pipeline. Despite challenges in profitability, the company continues to attract investor interest due to its potential for future growth, including multiple independent launches planned for 2026.
On February 25, 2026, Ionis reported its fourth quarter and full-year 2025 earnings before the market opened. The company posted an earnings per share (EPS) of -$1.41, which was below the estimated EPS (consensus around -$1.23). However, Ionis exceeded revenue expectations, reporting $203 million compared to the estimated ~$156 million. This revenue figure represented an ~11% decline year-over-year (from ~$227 million in Q4 2024), but surpassed the Zacks Consensus Estimate by ~30%.
Despite the year-over-year revenue decline in Q4, Ionis has consistently outperformed revenue estimates in recent quarters. The company generated $203 million in revenue for the quarter ending December 2025, a decrease from the $227 million reported in the same quarter the previous year. Notably, commercial revenue grew strongly (up ~64% to ~$141 million in Q4), driven by products like TRYNGOLZA, offsetting declines in royalties (e.g., SPINRAZA) and R&D revenue. Ionis’ ability to surpass revenue expectations highlights its strategic positioning and potential for continued success in 2026, as noted by CEO Brett P. Monia, Ph.D., with emphasis on upcoming launches (e.g., olezarsen for sHTG, zilganersen for AxD, and growth from DAWNZERA, WAINUA, etc.).
Ionis Pharmaceuticals has a negative price-to-earnings (P/E) ratio of approximately -50, indicating current unprofitability. The price-to-sales ratio is about 13, suggesting investors are willing to pay a premium for revenue amid pipeline expectations. The enterprise value to sales ratio is approximately 13, reflecting the company’s valuation relative to revenue. Despite challenges in generating positive cash flow, Ionis maintains a strong current ratio of approximately 2.79, indicating its ability to cover short-term liabilities with short-term assets.
